Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Magnit will open 2 thousand bakeries in convenience stores

3/28/23 MGNT

MTS buys controlling stake in a developer of telematics for commercial fleets

3/28/23 MTSS

VK prepares infrastructure in case YouTube is shut down

3/28/23 VKCO

SPB Exchange keeps securities from Hong Kong in unfriendly depositories

3/28/23 SPBE

Rusal shareholders denied Sual Partners access to documents

3/27/23 RUAL

SFI reported for 2022 according to IFRS

3/27/23 SFIN

Winery Jubilee reached a record revenue and profit

3/27/23 ABRD

Carnival's revenues grew 2.7 times in the first quarter

3/27/23 CCL

Acron reported for 2022 according to RAS

3/27/23 AKRN

Yandex intends to make the hub in Serbia the main office for work in the European market

3/27/23 YNDX